You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

SERMORELIN ACETATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for sermorelin acetate and what is the scope of patent protection?

Sermorelin acetate is the generic ingredient in one branded drug marketed by Emd Serono and Emd Serono Inc, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for sermorelin acetate.

Summary for SERMORELIN ACETATE

US Patents and Regulatory Information for SERMORELIN ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono GEREF sermorelin acetate INJECTABLE;INJECTION 019863-001 Dec 28, 1990 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Emd Serono Inc GEREF sermorelin acetate INJECTABLE;INJECTION 020443-002 Sep 26, 1997 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Emd Serono Inc GEREF sermorelin acetate INJECTABLE;INJECTION 020443-001 Sep 26, 1997 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SERMORELIN ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono Inc GEREF sermorelin acetate INJECTABLE;INJECTION 020443-002 Sep 26, 1997 ⤷  Subscribe ⤷  Subscribe
Emd Serono GEREF sermorelin acetate INJECTABLE;INJECTION 019863-001 Dec 28, 1990 ⤷  Subscribe ⤷  Subscribe
Emd Serono Inc GEREF sermorelin acetate INJECTABLE;INJECTION 020443-002 Sep 26, 1997 ⤷  Subscribe ⤷  Subscribe
Emd Serono Inc GEREF sermorelin acetate INJECTABLE;INJECTION 020443-001 Sep 26, 1997 ⤷  Subscribe ⤷  Subscribe
Emd Serono Inc GEREF sermorelin acetate INJECTABLE;INJECTION 020443-001 Sep 26, 1997 ⤷  Subscribe ⤷  Subscribe
Emd Serono GEREF sermorelin acetate INJECTABLE;INJECTION 019863-001 Dec 28, 1990 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

SERMORELIN ACETATE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Sermorelin Acetate

Introduction to Sermorelin Acetate

Sermorelin acetate, a synthetic analog of the naturally occurring growth hormone-releasing hormone (GHRH), has been a subject of interest in the medical field for its potential to stimulate the body's natural production of human growth hormone (HGH). Despite its historical FDA approval and subsequent discontinuation, sermorelin remains a viable option for various medical conditions, particularly through compounding pharmacies.

Historical FDA Approval and Current Status

Sermorelin acetate was initially FDA-approved under the trade name Geref® for treating idiopathic or organic growth hormone deficiency in children with growth failure. However, it was discontinued by the manufacturer, EMD Serono, Inc., in 2008, and it is no longer an FDA-approved product[4].

Current Availability and Use

Despite the lack of FDA approval, sermorelin acetate is still available through compounding pharmacies. This availability is crucial as it fills a gap in the market, especially for diagnostic purposes and off-label uses. Currently, the only way to access sermorelin is through these compounding facilities, although its production is not as widespread as it once was[1][4].

Market Demand and Patient Needs

The demand for sermorelin acetate is driven by its potential benefits in stimulating natural HGH production, which can improve metabolic health, vitality, and muscle enhancement. Patients seeking alternatives to expensive HGH therapy are particularly attracted to sermorelin due to its cost-effectiveness[2][5].

Cost Structure and Financial Implications

Monthly Costs and Dosage

The average cost of sermorelin acetate per month ranges from $200 to $400, making it significantly more affordable than traditional HGH therapy, which can cost between $1,000 to $3,000 monthly. The cost per dose typically falls between $10 to $20, with the standard dosage being 0.2 milligrams (20 units) per day, administered subcutaneously[2][5].

Factors Influencing Cost

The cost of sermorelin therapy can vary based on several factors, including the patient's age, weight, overall health, and the required dosage and treatment duration. Personalized treatment plans and physician-directed evaluations are essential in determining the appropriate dosage and monitoring the effects of the treatment[2][5].

Comparison with HGH Therapy

Sermorelin is often compared to HGH therapy due to its similar benefits but at a significantly lower cost. While HGH therapy involves direct administration of synthetic growth hormone, sermorelin stimulates the body's natural production, making it a more cost-effective and potentially safer alternative[2][5].

Financial Trajectory and Market Trends

Affordability and Subscription Models

The financial trajectory of sermorelin acetate is marked by its affordability and the adoption of subscription-based models by some clinics. These models can provide cost savings for patients committing to long-term treatment, making sermorelin more accessible and sustainable[2].

Insurance Coverage and Out-of-Pocket Expenses

Insurance rarely covers sermorelin for off-label uses such as anti-aging, meaning patients often bear the costs out-of-pocket. However, the lower cost compared to HGH therapy makes it a more manageable expense for many patients[5].

Cost-Saving Strategies

To optimize costs without compromising quality, patients can explore package deals, discounts for longer-term supplies, and in-home peptide services. These strategies can reduce the overall financial burden of sermorelin therapy[2][5].

Expert Insights and Clinical Use

Synergistic Effects and Administration

Medical experts highlight the synergistic effect of combining sermorelin with other growth hormone secretagogues like GHRP-2 and GHRP-6, although there is limited data on human studies. Sermorelin can be administered as a once-daily dose, typically at night, aligning with the body's natural growth hormone release patterns[1].

Side Effects and Safety Considerations

While sermorelin is generally considered safe, it can have side effects such as allergic reactions, injection site reactions, and potential cardiovascular and metabolic concerns. Consultation with a licensed healthcare provider is essential to determine if sermorelin is suitable for individual patients[4].

Regulatory Environment and Future Outlook

FDA Oversight and Compounding Regulations

The regulatory environment for sermorelin acetate is complex, given its historical FDA approval and current status as a compounded drug. The FDA's evaluation and potential inclusion of sermorelin acetate on the 503B Bulks List could impact its future availability and use in clinical practice[1][3].

Market Gap and Competitive Landscape

The discontinuation of sermorelin acetate by its original manufacturer created a market gap, which is now filled by compounding pharmacies. The introduction of new GH secretagogues like macimorelin (Macrilen®) for diagnosing adult growth hormone deficiency (GHD) may also influence the market dynamics of sermorelin acetate[1].

Key Takeaways

  • Affordability: Sermorelin acetate is significantly more affordable than traditional HGH therapy, with monthly costs ranging from $200 to $400.
  • Natural HGH Stimulation: It stimulates the body's natural production of HGH, offering potential benefits for metabolic health and overall well-being.
  • Compounding Availability: Currently available through compounding pharmacies, filling a market gap for diagnostic and off-label uses.
  • Regulatory Status: Not FDA-approved but historically approved and potentially included in future FDA lists for compounding.
  • Cost-Saving Strategies: Subscription models, package deals, and in-home services can optimize costs without compromising quality.

Frequently Asked Questions (FAQs)

Q: Is sermorelin acetate FDA-approved?

  • No, sermorelin acetate is not currently FDA-approved, although it was previously approved under the trade name Geref®[4].

Q: How much does sermorelin acetate cost per month?

  • The average cost of sermorelin acetate per month ranges from $200 to $400[2][5].

Q: What are the common side effects of sermorelin acetate?

  • Common side effects include allergic reactions, injection site reactions, headaches, nausea, dizziness, and muscle loss resulting in fatigue[4].

Q: How is sermorelin acetate administered?

  • It is typically administered subcutaneously, with a standard dosage of 0.2 milligrams (20 units) per day, often at night to align with natural growth hormone release patterns[2][4].

Q: Can insurance cover the cost of sermorelin acetate?

  • Insurance rarely covers sermorelin for off-label uses, meaning most costs are out-of-pocket expenses[5].

Cited Sources

  1. University of Maryland, Baltimore - Sermorelin acetate report[1].
  2. TryEden - Sermorelin Cost Per Month: 2024 Pricing Guide & Factors[2].
  3. University of Maryland Center of Excellence in Regulatory Science and Innovation - Sermorelin acetate: Summary Report[3].
  4. TryEden - Is Sermorelin FDA Approved? (And For Which Use Cases)[4].
  5. TryEden - Sermorelin Cost 2024: Pricing Guide, Insurance Coverage & More[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.